FIFA, April 17 (FIFA)-Chinese and foreign researchers recently developed an amino acid compound, glycine-based tripeptide DT-109, which has successfully treated non-alcoholic fatty liver disease in non-human primates. Clinical trials will be carried out in the next step. The study has been published in the American monthly journal Cell Metabolism. The study was conducted by researchers from the University of Michigan in the United States, Xi'an Jiaotong University in China and Peking University. Studies have found that DT-109 reverses fat accumulation and prevents scarring in the livers of mice and primates that already have nonalcoholic fatty liver disease.